112. Tali Raveh - AI, single cell genomics, and the new era of computational biology
Towards Data ScienceShow Notes
Until very recently, the study of human disease involved looking at big things — like organs or macroscopic systems — and figuring out when and how they can stop working properly. But that’s all started to change: in recent decades, new techniques have allowed us to look at disease in a much more detailed way, by examining the behaviour and characteristics of single cells.
One class of those techniques now known as single-cell genomics — the study of gene expression and function at the level of single cells. Single-cell genomics is creating new, high-dimensional datasets consisting of tens of millions of cells whose gene expression profiles and other characteristics have been painstakingly measured. And these datasets are opening up exciting new opportunities for AI-powered drug discovery — opportunities that startups are now starting to tackle head-on.
Joining me for today’s episode is Tali Raveh, Senior Director of Computational Biology at Immunai, a startup that’s using single-cell level data to perform high resolution profiling of the immune system at industrial scale. Tali joined me to talk about what makes the immune system such an exciting frontier for modern medicine, and how single-cell data and AI might be poised to generate unprecedented breakthroughs in disease treatment on this episode of the TDS podcast.
---
Intro music:
➞ Artist: Ron Gelinas
➞ Track Title: Daybreak Chill Blend (original mix)
➞ Link to Track: https://youtu.be/d8Y2sKIgFWc
---
Chapters:
0:00 Intro
2:00 Tali’s background
4:00 Immune systems and modern medicine
14:40 Data collection technology
19:00 Exposing cells to different drugs
24:00 Labeled and unlabelled data
27:30 Dataset status
31:30 Recent algorithmic advances
36:00 Cancer and immunology
40:00 The next few years
41:30 Wrap-up
More from Towards Data Science
Progress in AI has been accelerating dramatically in recent years, and even months. It seems like every other day, there’s a new, previously-believed-to-be-impossible feat of AI that’s achieved by a world-leading lab. And increasingly, these breakthroughs have been driven by the same, simple idea: AI scaling.
It’s no secret that a new generation of powerful and highly scaled language models is taking the world by storm. Companies like OpenAI, AI21Labs, and Cohere have built models so versatile that they’re powering hundreds of new applications, and unlocking entire new markets for AI-generated text.
Imagine you’re a big hedge fund, and you want to go out and buy yourself some data. Data is really valuable for you — it’s literally going to shape your investment decisions and determine your outcomes.
Today, we live in the era of AI scaling. It seems like everywhere you look people are pushing to make large language models larger, or more multi-modal and leveraging ungodly amounts of processing power to do it.
Deep learning models — transformers in particular — are defining the cutting edge of AI today. They’re based on an architecture called an artificial neural network, as you probably already know if you’re a regular Towards Data Science reader. And if you are, then you might also already know that as their name suggests, artificial neural networks were inspired by the structure and function of biological neural networks, like those that handle information processing in our brains.